Busulfan Alternatives Compared
Busulfan | Gleevec (imatinib) | Tasigna (nilotinib) |
|
---|
Busulfan | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Bone Marrow Transplantation, Chronic Myelogenous Leukemia, Thrombocythemia. Busulfan may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia. Tasigna may also be used for purposes not listed in this medication guide. |
||||||||||||||||
More about Busulfan | More about Gleevec (imatinib) | More about Tasigna (nilotinib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Busulfan has an average rating of 10.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 5% reported a negative effect. |
Tasigna has an average rating of 7.7 out of 10 from a total of 30 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Busulfan side effects |
View all Gleevec side effects |
View all Tasigna side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Tasigna prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Busulfex, Myleran | Other imatinib brands include: Imkeldi | Other nilotinib brands include: Danziten | ||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
N/A |
40 hours |
17 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 299 drugs are known to interact with Busulfan:
|
A total of 769 drugs are known to interact with Gleevec:
|
A total of 815 drugs are known to interact with Tasigna:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
June 26, 1954 |
May 10, 2001 |
October 29, 2007 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.